- Home
- BCAB vs OTLK Comparison
BCAB vs OTLK Comparison
Compare BCAB & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- OTLK
- Stock Information
- Founded
- BCAB 2007
- OTLK 2010
- Country
- BCAB United States
- OTLK United States
- Employees
- BCAB N/A
- OTLK N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BCAB Health Care
- OTLK Health Care
- Exchange
- BCAB Nasdaq
- OTLK Nasdaq
- Market Cap
- BCAB 40.5M
- OTLK 42.8M
- IPO Year
- BCAB 2020
- OTLK 2016
- Fundamental
- Price
- BCAB $0.76
- OTLK $1.38
- Analyst Decision
- BCAB Hold
- OTLK Buy
- Analyst Count
- BCAB 3
- OTLK 5
- Target Price
- BCAB $1.00
- OTLK $5.25
- AVG Volume (30 Days)
- BCAB 1.4M
- OTLK 2.6M
- Earning Date
- BCAB 11-05-2025
- OTLK 08-14-2025
- Dividend Yield
- BCAB N/A
- OTLK N/A
- EPS Growth
- BCAB N/A
- OTLK N/A
- EPS
- BCAB N/A
- OTLK N/A
- Revenue
- BCAB $11,000,000.00
- OTLK $1,505,322.00
- Revenue This Year
- BCAB N/A
- OTLK N/A
- Revenue Next Year
- BCAB N/A
- OTLK $342.80
- P/E Ratio
- BCAB N/A
- OTLK N/A
- Revenue Growth
- BCAB N/A
- OTLK N/A
- 52 Week Low
- BCAB $0.24
- OTLK $0.79
- 52 Week High
- BCAB $2.53
- OTLK $6.98
- Technical
- Relative Strength Index (RSI)
- BCAB 52.28
- OTLK 55.68
- Support Level
- BCAB $0.61
- OTLK $1.28
- Resistance Level
- BCAB $1.06
- OTLK $1.48
- Average True Range (ATR)
- BCAB 0.13
- OTLK 0.12
- MACD
- BCAB -0.02
- OTLK 0.02
- Stochastic Oscillator
- BCAB 32.78
- OTLK 68.48
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.